Cambrex Acquires Q1 Scientific

Article

Deal expands CDMO’s presence in Europe

Cambrex, a contract development and manufacturing organization (CDMO) that offers drug substance, drug product, and analytical services across the entire drug lifecycle, has acquired Q1 Scientific, a provider of environmentally-controlled current good manufacturing practice (cGMP) stability storage services for the pharma, med device, and life science sectors.

Q1 Scientific’s state-of-the-art cGMP facility in Waterford, Ireland, is International Council on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)-validated to meet storage requirements of a variety of pharma projects, with options spanning from as cold as 80ºC (-112ºF) storage to 50ºC (122ºF), including a full range of humidity control. The 20,000 square-foot Waterford facility offers nearly 40 walk-in stability storage chambers, reach-in freezers, and stability units, along with ultra-low temperature freezers for biologic therapies.

“Stability storage and testing is a critical component of drug development and commercialization of new therapies. Q1 Scientific brings world-class capabilities to our ever-expanding portfolio of outsourced pharmaceutical services,” says Tom Loewald, Cambrex CEO. “This acquisition is a natural extension of our current offerings that will broaden and increase our expertise in this critical area, as well as our footprint in the European market.”

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.